





## RUNX1 (Ab-435) Antibody


| Product Code               | CSB-PA132524  |
|----------------------------|---|
| Storage                    | Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.   |
| Uniprot No.                | Q01196  |
| Immunogen                  | Synthesized non-phosphopeptide derived from Human AML1 around the phosphorylation site of serine 435 (S-N-S(p)-P-T).  |
| Raised In                  | Rabbit  |
| Species Reactivity         | Human, Mouse  |
| Specificity                | The antibody detects endogenous levels of total AML1 protein.   |
| <b>Tested Applications</b> | ELISA,WB;WB:1:500-1:3000  |
| Relevance                  | CBF binds to the core site, 5'-PYGPYGGT-3', of a number of enhancers and promoters, including murine leukemia virus, polyomavirus enhancer, T-cell receptor enhancers, LCK, IL-3 and GM-CSF promoters. The alpha subunit binds DNA and appears to have a role in the development of normal hematopoiesis. Isoform AML-1L interferes with the transactivation activity of RUNX1. Acts synergistically with ELF4 to transactivate the IL-3 promoter and with ELF2 to transactivate the mouse BLK promoter. Inhibits KAT6B-dependent transcriptional activation.  Miyoshi H., Proc. Natl. Acad. Sci. U.S.A. 88:10431-10434(1991). Sacchi N., Genes Chromosomes Cancer 11:226-236(1994). Nucifora G., Blood 81:2728-2734(1993). |
| Form                       | Rabbit IgG in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.   |
| Purification Method        | The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.   |
| Clonality                  | Polyclonal  |
| Alias                      | Acute myeloid leukemia 1 protein; CBF-alpha 2; CBFA2; Core-binding factor; alpha 2 subunit  |
| Product Type               | Polyclonal Antibody   |
| Species                    | Homo sapiens (Human)  |
| Target Names               | RUNX1   |
| Image                      |   |












Western blot analysis of extracts from HepG2 cells, treated with PMA (125ng/ml, 30mins), using AML1 (Ab-435) antibody.



Western blot analysis of extracts from 293 cells (Lane 2) and Hela cells (Lane 3), using AML1 (Ab-435) antiobdy. The lane on the left is treated with synthesized peptide.